---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-001075"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T04:44:54.081297+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Phio Pharmaceuticals appoints Robert Bitterman as President and CEO effective Feb 20, 2023

## Summary
- Bitterman, previously interim CEO since Sep 2022, appointed permanent President and CEO and remains Chair of the Board.
- Employment agreement provides $440,000 base salary, up to 40% annual bonus, and 11,000 RSUs vesting over 2 years.
- Bitterman has prior CEO experience at Cutanea Life Sciences and Isolagen; Board conducted a search before appointment.
- He will continue as principal executive and financial officer; no family relationships or reportable transactions disclosed.

## SEC filing metadata
- accession: 0001683168-23-001075
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316823001075/0001683168-23-001075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316823001075/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-001075
- JSON: https://secwatch.observer/filing/0001683168-23-001075.json
- Plain text: https://secwatch.observer/filing/0001683168-23-001075.txt

## Key facts
- Executive change
  Robert J. Bitterman was appointed as President and Chief Executive Officer and Chair of the Board at Phio Pharmaceuticals Corp..
  - Action: appointed
  - Role: President and Chief Executive Officer and Chair of the Board
  source text: On February 17, 2023, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) approved the appointment of Robert J. Bitterman, acting Executive Chairman of the Board and acting Interim Chief Executive Officer, to serve as the Company’s President and Chief Executive Officer and Chair of the Board, effective as of February 20, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533040/000168316823001075/0001683168-23-001075-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.